Back to results
US 2020/0002346 A1Published application
Pyrazolochlorophenyl compounds, compositions and methods of use thereof
AssigneeGenentech, Inc.
InventorsMark ZAK, F. Anthony ROMERO, Po-wai YUEN, Emily J. HANAN
Life of this patent
Estimating the term…
Abstract
Compounds of Formula I and methods of use as Janus kinase inhibitors are described herein.
Claims19
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is C2-C6alkenyl, C2-C6alkynyl, —(C0-C3alkyl)CN, —(C0-C3alkyl)ORa, —(C0-C3alkyl)Ra, —(C0-C3alkyl)SRa, —(C0-C3alkyl)NRaRb, —(C0-C3alkyl)OCF3, —(C0-C3alkyl)CF3, —(C0-C3alkyl)NO2, —(C0-C3alkyl)C(O)Ra, —(C0-C3alkyl)C(O)ORa, —(C0-C3alkyl)C(O)NRaRb, —(C0-C3alkyl)NRaC(O)Rb, —(C0-C3alkyl)S(O)1-2Ra, —(C0-C3alkyl)NRaS(O)1-2Rb, —(C0-C3alkyl)S(O) 12NRaRb, —(C0-C3alkyl)(5-6-membered heteroaryl) or —(C0-C3alkyl)phenyl, wherein R1 is optionally substituted by halogen, C1-C3alkyl, oxo, —CF3, —(C0-C3alkyl)ORc or —(C0-C3alkyl)NRcRd;
- each Ra is independently selected from the group consisting of hydrogen, C1-C6alkyl, C3-C6 cycloalkyl, 3-10 membered heterocyclyl, 5-6 membered heteroaryl, —C(O)Rc, —C(O)ORc, —C(O)NRcRd, —NRcC(O)Rd, —S(O)1-2Rc, —NRcS(O)1-2Rd and —S(O)1-2NRcRd, wherein any C3-C6 cycloalkyl, 3-10 membered heterocyclyl, and 5-6 membered heteroaryl of Ra is optionally substituted with Re;
- each Rb is independently selected from the group consisting of hydrogen and C1-C3alkyl, wherein said alkyl is optionally substituted halogen or oxo;
- each Rc and Rd is independently selected from the group consisting of hydrogen, 3-6 membered heterocyclyl, C3-C6 cycloalkyl, and C1-C3alkyl, wherein any 3-6 membered heterocyclyl, C3-C6 cycloalkyl, and C1-C3alkyl of Rc and Rd is optionally substituted by halogen or oxo;
- or Rc and Rd are taken together with the atom to which they are attached to form a 3-6-membered heterocyclyl, optionally substituted by halogen, oxo, —CF3 or C1-C3alkyl;
- each Re is independently selected from the group consisting of oxo, ORf, NRfRg, halogen, 3-10 membered heterocyclyl, C3-C6 cycloalkyl, and C1-C6alkyl, wherein any C3-C6 cycloalkyl and C1-C6alkyl of Re is optionally substituted by ORf, NRfRg, halogen, 3-10 membered heterocyclyl, oxo, or cyano, and wherein any 3-10 membered heterocyclyl of Re is optionally substituted by halogen, oxo, cyano, —CF3, NRhRk, 3-6 membered heterocyclyl, or C1-C3alkyl that is optionally substituted by halogen, oxo, ORf, or NRhRk;
- each Rf and Rg is independently selected from the group consisting of hydrogen, C1-C6alkyl, 3-6 membered heterocyclyl, and C3-C6 cycloalkyl, wherein any C1-C6alkyl, 3-6 membered heterocyclyl, and C3-C6 cycloalkyl of Rf and Rg is optionally substituted by Rm;
- each Rh and Rk is independently selected from the group consisting of hydrogen and C1-C6alkyl that is optionally substituted by halogen, cyano, 3-6 membered heterocyclyl, or oxo;
- or Rh and Rk are taken together with the atom to which they are attached to form a 3-6-membered heterocyclyl that is optionally substituted by halogen, cyano, oxo, —CF3 or C1-C3alkyl that is optionally substituted by halogen or oxo;
- each Rm is independently selected from the group consisting of halogen, cyano, oxo, C3-C6cycloalkyl, hydroxy, and NRhRk, wherein any C3-C6cycloalkyl of Rm is optionally substituted with halogen, oxo, cyano, or C1-C3alkyl;
- R2 is phenyl, 5-6 membered heteroaryl, C3-C6 cycloalkyl or 3-10 membered heterocyclyl, wherein R2 is optionally substituted by 1-5 Rn;
- each Rn is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, oxo, halogen, —(C0-C3 alkyl)CN, —(C0-C3 alkyl)ORo, —(C0-C3 alkyl)SRo, —(C0-C3 alkyl)NRoRp, —(C0-C3 alkyl)OCF3, —(C0-C3 alkyl)CF3, —(C0-C3 alkyl)NO2, —(C0-C3 alkyl)C(O)Ro, —(C0-C3 alkyl)C(O)ORo, —(C0-C3 alkyl)C(O)NRoRp, —(C0-C3 alkyl)NRoC(O)Rp, —(C0-C3 alkyl)S(O)1-2Ro, —(C0-C3 alkyl)NRoS(O)1-2Rp, —(C0-C3 alkyl)S(O)1-2NRoRp, —(C0-C3 alkyl)(C3-C6 cycloalkyl), —(C0-C3 alkyl)(3-6-membered heterocyclyl), —(C0-C3 alkyl)C(O)(3-6-membered heterocyclyl), —(C0-C3 alkyl)(5-6-membered heteroaryl) and —(C0-C3 alkyl)phenyl, wherein each Rn is independently optionally substituted with halogen, C1-C3 alkyl, oxo, —CF3, —(C0-C3 alkyl)ORr or —(C0-C3 alkyl)NRrRs;
- or two Rn are taken together to form —O(CH2)1-3O—;
- each Ro is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 3-6 membered heterocyclyl, —C(O)Rr, —C(O)ORr,
- —C(O)NRrRs, —NRrC(O)Rs, —S(O)1-2Rr, —NRrS(O)1-2Rs and —S(O)1-2NRrRs, wherein said alkyl, cycloalkyl and heterocyclyl are independently optionally substituted by oxo, C1-C3 alkyl, ORr, NRrRs or halogen;
- and each RP is independently selected from the group consisting of hydrogen and C1-C3 alkyl, wherein said alkyl is independently optionally substituted by halogen or oxo;
- or Ro and RP are taken together with the atom to which they are attached to form a 3-6-membered heterocyclyl, optionally substituted by halogen, oxo, —CF3 or C1-C3 alkyl;
- each Rr and Rs is independently selected from the group consisting of hydrogen and C1-C3 alkyl optionally substituted by halogen or oxo;
- or Rr and Rs are taken together with the atom to which they are attached to form a 3-6-membered heterocyclyl, optionally substituted by halogen, oxo, —CF3 or C1-C3 alkyl;
- and
- X is a 9-10 membered bicyclic heteroaryl that comprises 2 or 3 atoms each independently selected from the group consisting of O, S, and N, wherein the 9-10 membered bicyclic heteroaryl is optionally substituted with Ru;
- provided X is not,
- optionally substituted with Ru;
- each Ru is independently selected from the group consisting of hydrogen, halo, C1-C6 alkyl, C3-C6 cycloalkyl, 3-6 membered heterocyclyl, —ORv, —C(O)Rv, —C(O)ORv, —C(O)NRvRw, —NRvRw, —NRvC(O)Rw, —S(O)1-2R, —NRvS(O)1-2Rw and —S(O)1-2NRvRw, wherein said alkyl, cycloalkyl and heterocyclyl are independently optionally substituted by oxo, C1-C3 alkyl, —ORv, —NRvRw or halogen;
- and
- each Rv and Rw is independently selected from the group consisting of hydrogen and C1-C3 alkyl optionally substituted by halogen or oxo;
- or Rv and Rw are taken together with the atom to which they are attached to form a 3-6-membered heterocyclyl, optionally substituted by halogen, oxo, —CF3 or C1-C3 alkyl;
- provided the compound or pharmaceutically acceptable salt is not:
- or a pharmaceutically acceptable salt thereof.
27 more elements
A compound selected from the group consisting of:
- wherein:
- Ru1 is H or methyl;
- and
- RU2 is methyl or difluoromethyl;
- or a pharmaceutically acceptable salt thereof.
2 more elements
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.